The government has signaled its hard stance on invoking more compulsory licenses, this with the department of industrial policy and promotion (DIPP) listing three anti-cancer drugs as next compulsory licensing candidates. The industry has mixed views on it, reports CNBC-TV18's Archana Shukla.
first published: Jan 25, 2013 07:59 pm
A collection of the most-viewed Moneycontrol videos.
Live: Nifty registers third straight week of gains, up 2% in November | Closing Bell
Live: Can Nifty continue to step up its move to fresh peaks? | Opening Bell
Live: Sensex, Nifty retreat after mounting on new lifetime highs | Closing Bell
Live: Will bulls take Nifty to fresh lifetime highs today? | Opening Bell
